source
- STAT+: Astellas retries XLMTM gene therapy after deathsVeradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech newsSTAT · 4mo ago↗ source
- STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and moreIntellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedemaSTAT · 4mo ago↗ source
- Intellia CRISPR drug succeeds in late-stage study against rare swelling disorderThe findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.BioPharma Dive